Market TodayThemes and Stocks SummaryThematic Stock SearchCrypto SummaryFAQAbout
Generic Drug Makers Stocks$96.92
-0.03%4:00PM 01/26/2023
The list of companies include PRGO-Perrigo Company plc, CHRS-Coherus Biosciences Inc, BHC-Bausch Health Companies Inc, LCI-Lannett Co., Inc., EGRX-Eagle Pharmaceuticals Inc, COLL-Collegium Pharmaceutical Inc, ANIP-ANI Pharmaceuticals Inc, AMPH-Amphastar Pharmaceuticals Inc, TARO-Taro Pharmaceutical Industries, ACRS-Aclaris Therapeutics Inc, AMRX-Amneal Pharmaceuticals Inc
Latest intraday update before market close @ 20:45:42 PM 01/27/2023
Summary :
Average return is up 0.7%
Median return is up 0.3%
7 out of 12 stocks are up (limited to those with intraday pricing feeds).

Aggregated price index

Aggregated price index with volume information


  • Generic Drug Makers stocks down 0.0% on average while median return down -0.3% in a day
  • Generic Drug Makers stocks up 1.3% on average while median return up 0.5% in a week
  • Generic Drug Makers stocks up 12.1% on average while median return up 11.1% in a month
  • When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.

Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.

Related Stocks

Click on + to show price series and click on ticker for stock detail page

1 Day Return
1 Week Return
1 Month Return
PE Ratio
P/B (mrq)
P/S (ttm)
Earning Growth
Short %
Held By Institutions %
Price Pattern
Resist Support
Days Since Channel Change
Channel Slope (daily rate %)
14.2%\/\Above resistance159-0.2%
34.6%\/-\Above resistance159-0.4%
21.020.722.382.751.5B7%56%72-/\Above resistance159-0.2%
-24.5427.094.632.453380%955.8M17%111%67\/\/Above resistance1590.3%

* P/E and MarketCap are refreshed daily using IEX Cloud service. P/B, P/S, PEG, growth, short%, HelbyInstitute are refreshed weekly using Yahoo feeds. For latest stock stats please visit Yahoo Finance.

* Price Patter: / is upward trend, \ is downward trend, - is sideway. Click on the ticker to go to stock page to see Bayesian Trend model plot of the time series.

* Channel and change points are derived from Bayesian Trend model, where the channel slope is the growth rate while change points are those the model partition the time series.

Related ETFs (click on ticker for stock detail page)

leak data

  • 1M winners are : Winners for past month are $BHC 34.6%, $CHRS 29.5%, $COLL 24.0%, $EGRX 14.2%, $ACRS 11.5%
  • 1M losers are : Losers for past month are $RDY -0.2%, $AMRX -2.7%
  • 1W winners are : Winners for past week are $BHC 9.7%, $AMPH 7.7%, $ANIP 4.6%, $AMRX 3.4%, $COLL 1.8%
  • 1W losers are : Losers for past week are $EGRX -0.4%, $RDY -1.9%, $TARO -2.5%, $TEVA -2.7%, $CHRS -4.5%
Pick two stocks to compare:

Correlation Analysis

Index correlation analysis

Correlation for the past month is 19.1%, for the past 3 months is 25.5%

In the past month for a 5 days rolling window, the highest corrrelation is 32.4%, the lowest correlation is 2.4%, the latest correlation is 2.4%

When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.

Among pairwise correlation, the highest correlation is 71.7% between ACRS and ANIP

The lowest correlation is -30.1% between BHC and PRGO

Stock news

    Dr. Reddy’s Laboratories Limited (NYSE:RDY) Q3 2023 Earnings Call Transcript

    Dr. Reddy’s Laboratories Limited (NYSE:RDY) Q3 2023 Earnings Call Transcript January 25, 2023 Operator: Ladies and gentlemen, good day, and welcome to Dr. Reddy’s Laboratories Limited Q3 FY 2023 Earnings Conference Call. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions […]

    Down 30% in a Day, Is Catalyst Pharmaceuticals Doomed?

    Shareholders of Catalyst Pharmaceuticals (NASDAQ: CPRX) got a nasty shock on Jan. 23 when the company reported that a competitor, Teva Pharmaceutical Industries (NYSE: TEVA), was planning to make a generic version of its only marketed drug, Firdapse. With Catalyst's shares falling 30% in a day before slightly recovering, it's clear that the market is interpreting Teva's actions as severely threatening, and it's reasonable for investors to wonder if it's time to start looking for the door. Firs...

    Intercept Surges To Four-Month High After Staving Off Amneal's Generic For 11 Years

    Intercept reached a settlement with Amneal that delays a generic version of its only product. In response, ICPT stock surged Wednesday.

    Biotech Stock Roundup: BLUE Down on Share Issuance, CPRX Falls on Generic Filing & More

    Updates from bluebird (BLUE) and Catalyst Pharmaceuticals (CPRX) are the key highlights from the biotech sector during the past week.

    Nasdaq Bear Market: 3 Screaming Bargains That Can Double Your Money by 2025

    When the lights went out on 2022, all three major U.S. stock indexes had delivered their worst returns since 2008. While the Nasdaq losing a third of its value in such a short time frame is undoubtedly brutal for short-term traders, it represents a generational opportunity for patient investors to snag high-quality stocks at a discount. The first surefire bargain that has the potential to double your money by mid-decade is brand-name and generic-drug producer Teva Pharmaceutical Industries (NY...

    Taro Provides Results for December 31, 2022


    Catalyst (CPRX) Down on TEVA's FDA Filing for Firdapse Generic

    Catalyst Pharmaceuticals (CPRX) receives a notice letter stating that Teva Pharmaceuticals has filed an application to the FDA seeking approval for a generic version of Firdapse.

    No. 1 IBD 50 Stock Catalyst Tanks As Teva Looks To Knock Off Its Only Product

    Teva said Monday it plans to knock off Catalyst's only approved drug and CPRX stock — which has sat atop the IBD 50 for weeks — crashed.

    Catalyst Pharma Shares Take A Hit As Teva Files For Generic Version Of Its Lead Product

    Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) has received a Notice Letter stating that Teva Pharmaceutical Industries Ltd (NYSE: TEVA) submitted an abbreviated marketing application to the FDA for a generic version of Firdapse in the U.S. In the Notice Letter, Teva states that it intends to market a generic version of Firdapse before the expiration of Catalyst's patents covering U.S. patents expiring up to February 2037. Teva's Notice Letter states that its ANDA contains a Paragraph IV Certificat

    12 Most Undervalued Pharma Stocks To Buy According To Hedge Funds

    In this article, we discuss 12 most undervalued pharma stocks to buy according to hedge funds. If you want to see more stocks in this selection, check out 5 Most Undervalued Pharma Stocks To Buy According To Hedge Funds. Fitch Ratings has assigned a ‘Neutral’ outlook to the global pharmaceutical and biotech sector, indicating Fitch’s […]